tirzepatide and autoimmune disease associated encephalitis: A case report The Exhilirating Movement From Treatment
Description
As far as we know severe psychiatric complications represent just over 1% of reported adverse events, 30 largely consisting of depression, anxiety and suicidal ideation
This event has passed
The trial resulted in an average weight loss of 16.0 lbs/7.3 kg (7.9%) at the highest dose as a key secondary endpoint
Its unique mechanism of simultaneously targeting three distinct metabolic receptors makes it one of the most complex and promising compounds in current Phase 3 clinical research
Called multiple times and always told they would 'investigate' and no one gets back then billed again
